BioCentury
ARTICLE | Finance

Making the case for precompetitive clinical development

May 19, 2011 7:00 AM UTC

The Structural Genomics Consortium and Sage Bionetworks are spearheading an effort to build a precompetitive, pharma-backed public-private partnership to optimize the clinical validation of new therapeutic targets. By removing IP and data-access restrictions, the group hopes to create an environment that will eliminate redundant discovery programs and reduce the overall cost of R&D.

A newly established public-private partnership called the Archipelago to Proof of Clinical Mechanism (Arch2POCM) hopes to improve the efficiency and lower the costs of drug development by generating a portfolio of small molecules that hit new therapeutic targets and by carrying out early clinical work-up to Phase II clinical trials...